Welcome to our dedicated page for Amplia Therapeutics news (Ticker: INNMF), a resource for investors and traders seeking the latest updates and insights on Amplia Therapeutics stock.
Amplia Therapeutics Limited (INNMF) generates news primarily around its development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a strong focus on pancreatic cancer. Company announcements highlight clinical trial progress, scientific presentations, preclinical collaborations and intellectual property milestones related to its lead FAK inhibitor, narmafotinib (AMP945).
A major source of news is the ACCENT trial, a Phase 2a study in metastatic pancreatic cancer. Updates have covered interim data on objective response rates and progression-free survival when narmafotinib is combined with gemcitabine and nab-paclitaxel (Abraxane), as well as safety observations that the combination’s adverse effect profile is similar to chemotherapy alone. Amplia also reports on scientific exposure for ACCENT data, such as poster presentations at the American Society for Clinical Oncology Gastrointestinal Cancers Symposium.
News flow also includes the launch and progress of the AMPLICITY trial, which evaluates narmafotinib with FOLFIRINOX in advanced pancreatic cancer at sites in Australia and the United States, and updates on preclinical research collaborations. For example, Amplia has detailed a multi-phase collaboration with Korean company Next & Bio, using patient-derived pancreatic cancer cell models with kRAS mutations to study FAK inhibitors and their combinations with mutant kRAS inhibitors.
Another recurring theme in Amplia’s news is patent and intellectual property developments. The company has reported the grant of a key U.S. patent, alongside patents in Europe, Japan, India, Korea and Australia, protecting the specific form of narmafotinib being developed clinically and extending protection to at least 2040 in those regions.
Investors and observers following INNMF news can therefore expect updates on clinical trial data, conference presentations, collaborative research in pancreatic cancer, and the evolution of Amplia’s patent estate around narmafotinib.
Amplia Therapeutics (OTCQB:INNMF) received a Certificate of Grant from the US Patent and Trademark Office for a patent titled A salt and crystal form of a FAK inhibitor, extending protection for the company's clinically developed FAK inhibitor narmafotinib to at least 2040 in the US and other jurisdictions. The grant follows a September 2025 notification of allowance and complements existing patents already granted in Europe, Japan, India, Korea and Australia. The patent specifically protects the particular salt/crystal form of narmafotinib being developed clinically. The company stated protection in additional regions is under review by respective patent offices and said the grants strengthen narmafotinib's long-term intellectual property position.